Skip to content

Thursday, December 26

About
Contact Us
Disclaimer
Privacy Policy
Terms

World
Politics
Business
Money
Technology
Entertainment
Sports
Health
Travel

Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion

October 8, 2023

The deal expands the pharmaceutical company’s portfolio of cancer drugs.

Posted in World

Tagged in acquisitions, Acquisitions/Mergers, Acquisitions/Mergers/Shareholdings, Biopharmaceuticals, Biotechnology Services, BMY, Bristol Myers Squibb, C&E Industry News Filter, Cancer, Cancer Drugs, Content Types, corporate, Corporate Actions, corporate strategy, Corporate Strategy/Planning, Corporate/Industrial News, Factiva Filters, general news, health, healthcare, Healthcare/Life Sciences, industrial news, life sciences, Medical Conditions, medications, mergers, Mirati Therapeutics, MRTX, Ownership Changes, Pharmaceuticals, Physical Asset Transactions, planning, political, Political/General News, shareholdings, specialized drugs, Specialized Drugs/Medications, SYND, WSJ-PRO-WSJ.com

PrevReliance General Insurance gets Rs 922 crore GST notices from DGGI

NextElon Musk told X users to follow accounts known for lies for Israel updates

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.

Search

Recent Posts

10 fishes that can be kept in small aquariums
Is There An Olympic Moment You’ll Never Forget?
LeBron James intends to sign a new deal with LA Lakers
The Supreme Court Just Made a Massive Power Grab
Beryl, the Season’s First Hurricane, Is Expected to Intensify

Recent Comments

No comments to show.

WordPress Theme | Viral News by HashThemes